VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Moul Discusses the Long-Term Tolerability and Efficacy of Degarelix

Judd W. Moul, MD
Published: Thursday, Jul 03, 2014

Judd W. Moul, MD, director, Duke Prostate Center, James H. Semans, MD, Professor of Surgery, Duke University Medical Center, discusses the 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix.

Moul says the study originally compared degarelix to leuprolide to treat men with advanced prostate cancer. Initial results showed that monthly degarelix and monthly leuprolide were equivalent over the first year. However degarelix did better at lowering testosterone levels quickly in the first two months than leuprolide, Moul says.

Now it has been discovered that there are long-term benefits to treating patients with degarelix compared to leuprolide. The disease-free survival appears to be better with degarelix versus leuprolide, Moul says.

Judd W. Moul, MD, director, Duke Prostate Center, James H. Semans, MD, Professor of Surgery, Duke University Medical Center, discusses the 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix.

Moul says the study originally compared degarelix to leuprolide to treat men with advanced prostate cancer. Initial results showed that monthly degarelix and monthly leuprolide were equivalent over the first year. However degarelix did better at lowering testosterone levels quickly in the first two months than leuprolide, Moul says.

Now it has been discovered that there are long-term benefits to treating patients with degarelix compared to leuprolide. The disease-free survival appears to be better with degarelix versus leuprolide, Moul says.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x